Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors
Author Information
Author(s): Lutimba Stuart, Saleem Baraya, Aleem Eiman, Mansour Mohammed A., Ruiz Patricia
Primary Institution: London South Bank University
Hypothesis
Can triamterene act as a dual inhibitor for VEGFR-2 and c-Met receptors?
Conclusion
Triamterene shows promise as a dual inhibitor of VEGFR-2 and c-Met, potentially improving cancer treatment outcomes.
Supporting Evidence
- Triamterene exhibited significant binding affinity to both VEGFR-2 and c-Met.
- The study identified triamterene as a dual inhibitor through molecular docking and dynamics simulations.
- Key interactions were observed with critical residues in both proteins.
- Triamterene's potential for repurposing in cancer therapy is supported by its established safety profile.
Takeaway
Researchers found that triamterene, a drug usually used for high blood pressure, might help fight cancer by blocking two important proteins that help tumors grow.
Methodology
The study used molecular dynamics simulations and docking analysis to evaluate the binding of FDA-approved drugs to VEGFR-2 and c-Met.
Potential Biases
Potential off-target effects and side effects of triamterene in cancer patients need further investigation.
Limitations
The study's computational models may not fully capture the dynamic nature of proteins in physiological conditions.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website